During the forecast period, the globalmelanocyte protein PMEL market is expected to rise at a considerable CAGR (2022-2028). Premelanosome protein (PMEL) or silver locus protein homolog is another name for Melanocyte Protein PMEL (SILV). The PMEL gene in humans is responsible for encoding this protein. Melanocyte protein is essential for the formation of melanosomes. The increased prevalence of melanoma around the world is a primary factor driving the market's rise. According to the American Cancer Society, in 2022, an estimated 99,780 new melanomas will be diagnosed globally. Out of which about 57,180 new cases will be diagnosed in men and 42,600 in women.
Additionally, the risk of melanoma increases with age. Further, 65 years is the average age of people when it is diagnosed. However, melanoma can also occur among people under 30 years of age. It is also one of the most common cancers in young adults. Although, it is more common in men, however, the rates are higher in women than in men before 50 years of age. Apart from this, this protein plays an important role during pigment formation and eumelanosome development. It is also used as a melanoma tumour marker owing to its assumed melanocyte-specific expression at the protein level. The
increasing demand for drugs such as Dacarbazine can restrain the melanocyte protein PMEL market
Impact of COVID-19 on Global Melanocyte Protein PMEL Market.
Covid-19 has a positive impact on the global melanocyte protein PMEL market. Several lines of emerging evidence suggest that vitamin D signaling, targeting several immune-mediated pathways, may offer potential benefits at different stages of SARS-CoV-2 infection. Apart from the well-known limiting effects of melanin on endogenous vitamin D production, the possible crosstalk between the pigmentary and immunological systems may additionally, demand special consideration in light of the present epidemic. These raise the demand for melanocyte protein PMEL market across the globe.
Segmental Outlook
The global melanocyte protein PMEL market is segmented based on type and application. Based on type, the market is segmented into AE-M vaccine, SCIB-1, VPI-121, and others. Based on application, the market is segmented into glioblastoma multiforme,melanoma, and metastatic melanoma.
Global Melanocyte Protein PMEL Market Share by Type, 2021 (%)
AE-M Vaccine Segment is Holding a Prominent Share in the Global Melanocyte Protein PMEL Market.
Based on type, AE-M vaccines are predicted to grow the most in the melanocyte protein PMEL market. Excision is the surgical removal of skin cancer additionally, some healthy skin tissue surrounding it (margin). A local anesthetic is utilized to numb the region during this treatment. The incision is stitched closed once the malignant region has been removed. A skin graft or flap may be required if the incision is large. If the excision operation leaves a scar, reconstructive surgery may be required; which in turn may drive the growth of this market segment.
Regional Outlooks
The global melanocyte protein PMEL market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America).
Global Melanocyte Protein PMEL MarketGrowth, by Region 2022-2028
North America is expected to dominate the Global Melanocyte Protein PMEL market
The North America region is predicted to be dominated in the melanocyte protein PMEL market. Melanoma had been identified in 91,270 new cases in the US in 2018. It is most usually diagnosed in non-Hispanic whites, with a 26 (per 100,000) annual incidence rate, compared to 4 (per 100,000) in Hispanics and 1 (per 100,000) in blacks.For instance, In July 2014, the US Surgeon General issued a Call to Action to Prevent Skin Cancer, highlighting the disease's heightened and expanding burden. The goal of this project is to raise awareness and encourage all Americans to engage in skin cancer prevention measures. Such measure across the region has driven the regional market growth.
Market Players Outlook
The major companies serving the global melanocyte protein PMEL marketinclude ImmunoCellular Therapeutics, Ltd., Vault Pharma Inc., Antigen Express, Inc., Immunomic Therapeutics, Inc., Scancell Holdings Plc, and others.To enhance their market share, industry participants are employing a number of critical techniques. For instance, the US Food and Drug Administration has approved the Biologics License Application for IMLYGICTM (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for nodal lesions in patients with melanoma recurrent after initial surgery (FDA). IMLYGIC has been demonstrated to have no effect on overall survival or visceral metastases. The FDA has approved IMLYGIC, the first oncolytic viral therapy, based on the therapeutic effect observed in a key study.
The Report Covers
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Melanocyte Protein PMEL Market
• Recovery Scenario of Global Melanocyte Protein PMEL Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1.ImmunoCellular Therapeutics, Ltd.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Vault Pharma Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Antigen Express, Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. Swot Analysis
3.3.4. Recent Developments
3.4. Immunomic Therapeutics, Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5.Scancell Holdings Plc
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Melanocyte Protein PMEL Market by Type
4.1.1. AE-M vaccine
4.1.2. SCIB-1
4.1.3. VPI-121
4.1.4. Others
4.2. Global Melanocyte Protein PMEL Market by Application
4.2.1.Glioblastoma Multiforme
4.2.2.Melanoma
4.2.3. Metastatic Melanoma
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1.UK
5.2.2.Germany
5.2.3.Italy
5.2.4.Spain
5.2.5.France
5.2.6.Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Amgen Inc.
6.2. Bristol Myers Squibb
6.3. F. Hoffmann-La Roche Ltd.
6.4. GlaxoSmithKline plc
6.5. Merck & Co.
6.6. Novartis AG
6.7. Pfizer Inc.
6.8. Regeneron Pharmaceuticals, Inc.
6.9. Sun Pharmaceutical Industries Ltd.
6.10. Sarabhai Piramal Pharmaceuticals Ltd.
1. GLOBAL MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL AE-M VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL SCIB-1IN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL VPI-121IN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL OTHERS TYPE MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028($ MILLION)
7. GLOBAL MELANOCYTE PROTEIN PMEL FOR INGLIOBLASTOMA MULTIFORME TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
8. GLOBAL MELANOCYTE PROTEIN PMEL FOR MELANOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
9. GLOBAL MELANOCYTE PROTEIN PMEL MARKET FOR METASTATIC MELANOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028($ MILLION)
11. NORTH AMERICAN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
13. NORTH AMERICAN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
14. EUROPEAN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. EUROPEAN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028($ MILLION)
16. EUROPEAN MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
20. REST OF THE WORLD MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. REST OF THE WORLD MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
22. REST OF THE WORLD MELANOCYTE PROTEIN PMEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL MELANOCYTE PROTEIN PMEL MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL MELANOCYTE PROTEIN PMEL MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL MELANOCYTE PROTEIN PMEL MARKET, 2021-2028 (%)
4. GLOBAL MELANOCYTE PROTEIN PMEL MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL AE-M VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL SCIB-1IN MELANOCYTE PROTEIN PMEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL VPI-121IN MELANOCYTE PROTEIN PMEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL OTHER TYPE MELANOCYTE PROTEIN PMEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL MELANOCYTE PROTEIN PMEL MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
10. GLOBAL MELANOCYTE PROTEIN PMEL FOR GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL MELANOCYTE PROTEIN PMEL FOR INMELANOMA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL MELANOCYTE PROTEIN PMEL FOR METASTATIC MELANOMA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL MELANOCYTE PROTEIN PMEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. US MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
15. CANADA MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
16. UK MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
17. FRANCE MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
18. GERMANY MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
19. ITALY MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
20. SPAIN MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
21. REST OF EUROPE MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
22. INDIA MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
23. CHINA MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
24. JAPAN MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
25. SOUTH KOREA MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF ASIA-PACIFIC MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF THE WORLD MELANOCYTE PROTEIN PMEL MARKET SIZE, 2021-2028 ($ MILLION)